Validation of ICD-9-CM codes to identify gastrointestinal perforation events in administrative claims data among hospitalized rheumatoid arthritis patients

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 11, 2011, Pages 1150-1158

  Curtis, Jeffrey R ^a   Chen, Shih Yin ^b   Werther, Winifred ^c   John, Ani ^c   Johnson, David A ^d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c GENENTECH INC   (United States)

^d EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Administrative claims; Gastrointestinal perforation; Rheumatoid arthritis; Validation

Indexed keywords

ALGORITHM; ARTICLE; DATA BASE; DIGESTIVE SYSTEM PERFORATION; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ARTHRITIS, RHEUMATOID; CLINICAL CODING; CONFIDENCE INTERVALS; CURRENT PROCEDURAL TERMINOLOGY; DATABASES, FACTUAL; EPIDEMIOLOGIC STUDIES; ESOPHAGEAL PERFORATION; FEMALE; HOSPITALIZATION; HUMANS; INSURANCE CLAIM REVIEW; INTERNATIONAL CLASSIFICATION OF DISEASES; INTESTINAL PERFORATION; MALE; MEDICAL RECORDS; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MIDDLE AGED; MODELS, STATISTICAL; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; YOUNG ADULT;

EID: 80555150701     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2215     Document Type: Article

References (32)

1. Gastrointestinal perforation. MedlinePlus Medical Encyclopedia. Accessed November 2008. http://www.nlm.nih.gov/MEDLINEPLUS/ency/article/000235.htm.
2. Lanas A, Perez-Aisa MA, Feu F, et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 2005 Aug; 100: 1685-1693.
3. Sostres C, Gargallo CJ, Arroyo MT, Lanas A. Review: adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol 2010 Apr; 24(2): 121-132.
4. Laine L, Smith R, Min K, Chen C, Dubois RW. Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2006; 24: 751-767.
5. Lanas A, García-Rodríguez LA, Polo-Tomás M, et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol 2009; 104(7): 1633-1641.
6. Hernández-Díaz S, Rodríguez LA. Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies. J Clin Epidemiol 2002 Feb; 55(2): 157-163.
7. Bevis PJ, Bird HA, Lapham G. An open study to assess the safety and tolerability of meloxicam 15mg in subjects with rheumatic disease and mild renal impairment. Br J Rheumatol 1996 Apr; 35Suppl 1: 56-60.
8. Blackburn WD, Jr., Prupas HM, Silverfield JC, et al. Tenidap in rheumatoid arthritis. A 24-week double-blind comparison with hydroxychloroquine-plus-piroxicam, and piroxicam alone. Arthritis Rheum 1995 Oct; 38(10): 1447-1456.
9. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000 Nov 23; 343(21): 1520-1528, 2 p following 1528.
10. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008 Nov; 67(11): 1516-1523.
11. Furst DE, Kolba KS, Fleischmann R, et al. Meloxicam Rheumatoid Arthritis Investigators. Dose response and safety study of meloxicam up to 22.5mg daily in rheumatoid arthritis: a 12week multicenter, double blind, dose response study versus placebo and diclofenac. J Rheumatol 2002 Mar; 29(3): 436-446.
12. Huskisson EC, Ghozlan R, Kurthen R, Degner FL, Bluhmki E. A long-term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis. Br J Rheumatol 1996 Apr; 35Suppl 1: 29-34.
13. Kawai S, Tanaka K, Ohno I, Utsunomiya K, Seino Y. Safety of long-term tacrolimus therapy for rheumatoid arthritis: an open-label, uncontrolled study in non-elderly patients. Mod Rheumatol 2008; 18(4): 345-353.
14. Laine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003 Feb; 124(2): 288-292.
15. Neustadt DH. Double blind evaluation of the long-term effects of etodolac versus ibuprofen in patients with rheumatoid arthritis. J Rheumatol Suppl 1997 Feb; 47: 17-22.
16. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000 Sept 13; 284(10): 1247-1255.
17. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995 Aug 15; 123(4): 241-249.
18. Simon LS, Hatoum HT, Bittman RM, Archambault WT, Polisson RP. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial. Fam Med Mar 1996; 28(3): 204-210.
19. Wojtulewski JA, Schattenkirchner M, Barceló P, et al. A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5mg daily and naproxen 750mg daily in patients with rheumatoid arthritis. Br J Rheumatol. 1996 Apr; 35(Suppl 1): 22-28.
20. Curtis JR, Xie F, Chen L, et al. The incidence of gastrointestinal perforations among rheumatoid arthritis patients. Arthritis Rheum. 2011 Feb; 63(2): 346-351.
21. Cohen R, Robinson D Jr, Paramore C, Fraeman K, Renahan K, Bala M. Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002. Inflamm Bowel Dis 2008 Jun; 14(6): 738-743.
22. Bradley JR. TNF-mediated inflammatory disease. J Pathol 2008 Jan; 214(2): 149-160. Review.
23. Lazzerini PE, Capecchi PL, Selvi E, et al. Hyperhomocysteinemia, inflammation and autoimmunity. Autoimmun Rev 2007 Aug; 6(7): 503-509. Review.
24. Barcellos LF, Kamdar BB, Ramsay PP, et al. Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study. Lancet Neurol 2006 Nov; 5(11): 924-931.
25. Rhodes JM, Collins P. Lessons for inflammatory bowel disease from rheumatology. Dig Liver Dis 2006 Mar; 38(3): 157-162. Review.
26. Criswell LA, Pfeiffer KA, Lum RF, et al. Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. Am J Hum Genet 2005 Apr; 76(4): 561-571.
27. Witowski J, Ksiazek K, Jörres A. Interleukin-17: a mediator of inflammatory responses. Cell Mol Life Sci 2004 Mar; 61(5): 567-579. Review.
28. Abraham NS, Cohen DC, Rivers B, Richardson P. Validation of administrative data used for the diagnosis of upper gastrointestinal events following nonsteroidal anti-inflammatory drug prescription. Aliment Pharmacol Ther 2006; 24: 299-306.
29. Cattaruzzi C, Troncon MG, Agostinis L, García Rodríguez LA. Postivie predictive value of ICD-9th codes for upper gastrointestinal bleeding and perforation in the SISR database. J Clin Epidemiol 1999; 52(6): 499-502.
30. Raiford DS, Perez GS, García Rodríguez LA. Positive predictive value of ICD-9 codes in the identification of cases of complicated peptic ulcer disease in the Saskatchewan Hospital automated database. Epidemiology 1996; 7: 101-104.
31. Wahl PM, Rodgers K, Schneeweiss L, et al. Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population. Pharmacoepidemiol Drug Saf 2010 Jun; 19(6): 596-603.
32. Altman DG, Bland JM. Diagnostic tests 2: Predictive values. Br Med J 1994 Jul; 309(6947): 102.